This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve lung cancer treatment strategies.
The webinar will also offer the opportunity for real-time interaction between audience and experts.
Christian Rolfo, Maximilian Diehn
Welcome and Introduction, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
Current Status of MRD and Plasma Monitoring for Resectable Lung Cancer, Prof. Christian Rolfo, Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, NY, US
The Role of plasma-based cfDNA Testing in Management of EGFR or ALK Positive Lung Cancer, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
Novel Technology in Liquid Biopsy for Lung Cancer, Prof. Maximilian Diehn, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, US
Closing Remarks, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
- Understand the current status of minimal residual disease and plasma monitoring for resectable lung cancer
- Understand the role of plasma-based cfDNA testing in management of EGFR or ALK positive lung cancer
- Understand novel technologies in liquid biopsy for lung cancer